Basel, September 15, 2026 – TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company pioneering therapies targeting non-oncogene addiction in cancer, today announced the completion of its Phase I study of monotherapy TT125-802 (NCT06403436) and the presentation of final clinical data from the study at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. The data highlights TT125-802’s confirmed clinical activity as monotherapy in drug-resistant NSCLC and supports CBP/p300 inhibition as a novel therapeutic strategy to address transcriptional drug resistance in solid tumors.
TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026
Basel, September 15, 2026 – TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company pioneering therapies targeting non-oncogene addiction in cancer, today announced the completion of its Phase I study of monotherapy TT125-802 (NCT06403436) and the presentation of final clinical data from the study at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. The data highlights TT125-802’s confirmed clinical activity as monotherapy in drug-resistant NSCLC and supports CBP/p300 inhibition as a novel therapeutic strategy to address transcriptional drug resistance in solid tumors.
Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program
VIENNA, September 15, 2026 — Aitiologic, a precision medicine company developing tissue-resolved liquid biopsy solutions, today announced the close of a significantly oversubscribed €6.4 million (approximately $7.4 million) seed financing, co-led by Heal Capital and Ananda Impact Ventures. The financing will support ongoing large-scale validation and regulated product development of Aitios®, the company’s multi-modal cell-free DNA (cfDNA) platform, initially for first-trimester preeclampsia risk stratification. Dr. Gordon Sanghera CBE FRS, an established pioneer in molecular diagnostics, participated in the seed round as an investor and will join the company’s advisory board. To further advance the clinical translation of the preeclampsia lead program, Dr. Rebecca Ertl has been appointed Chief Medical Officer.
Nordic Climate Group expands Dutch offering with Bakker Vakkeuken
Nordic Climate Group expands Dutch offering with Bakker Vakkeuken
Nordic Climate Group breidt Nederlands aanbod uit met Bakker Vakkeuken
Nordic Climate Group breidt Nederlands aanbod uit met Bakker Vakkeuken
Nordic Climate Group växer i Nederländerna med Bakker Vakkeuken
Benzyl Chloride Market Size to Surpass USD 1,990.00 Million by 2035; Growing at 6.90% CAGR | SNS Insider
U.S. Market to Reach USD 418 Million by 2035; Europe to Grow to USD 474.19 Million Amid Rising Pharmaceutical and Specialty Chemical Demand
LearnEnglishAbc.com Expands Worldwide ESL Learning Platform With HOPE AI Tutor, Free Plan, and Read-Aloud Library
The platform combines structured English lessons, 164 graded books with narration, songs, grammar, and AI conversation practice to help learners build confidence in English.
Telxius Boosts Global Network Capacity and Efficiency with Nokia 800G Coherent Pluggable Deployment
Press Release
Telxius boosts global network capacity and efficiency with Nokia 800G Coherent Pluggable deployment
Finsei brings acquiring in-house for business clients
London, UK, Sept. 15, 2026 (GLOBE NEWSWIRE) — Businesses can now accept Visa and Mastercard payments through the same account as their transfers and cards
L’offre du groupement Atos, Open, Thales sélectionnée par l’UGAP pour ses marchés de prestations cloud et infrastructures
NewHydrogen Announces Strategic Collaboration with Utah San Rafael Energy Lab
The initial site assessment will evaluate USREL’s Orangeville, Utah facility as a potential host for future ThermoLoop® deployment
Increase of share capital in connection with the share option programme and subscription results
The Supervisory Board of AS Tallink Grupp (hereinafter the Group) resolved to increase the Group’s share capital by EUR 2,451,661 through the issuance of new ordinary shares. The resolution to increase the share capital was adopted in connection with the exercise of options issued under the share option programme approved by the Group’s General Meeting of Shareholders on 13 June 2023, in accordance with the terms and conditions of the share option programme.
Aktsiakapitali suurendamine seoses optsiooniprogrammiga ning märkimistulemused
AS-i Tallink Grupp (edaspidi: Kontsern) nõukogu otsustas suurendada Kontserni aktsiakapitali 2 451 661 euro võrra uute lihtaktsiate väljalaskmise teel. Aktsiakapitali suurendamise otsus võeti vastu Kontserni 13. juuni 2023. aasta üldkoosolekul kinnitatud optsiooniprogrammi raames väljastatud optsioonide realiseerimiseks vastavalt optsiooniprogrammi tingimustele.
Circular, the new independent firm founded by Spanish fund managers Pablo Cano and Álvaro Sanmartín, launches with more than 175 million euros under management
SkySail Strategies Outperforms Wall Street’s 30-Year Risk Standard With Proprietary AI Inference Model
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) —
State of the Art by SkySail, the Rubix VM RPT model predicts how far markets will move with less error than the models institutions have relied on since 1993.